Last reviewed · How we verify
131I-IPA
Iodine-131 labelled peptide for targeted radionuclide therapy
Iodine-131 labelled peptide for targeted radionuclide therapy Used for Prostate cancer, Neuroendocrine tumors.
At a glance
| Generic name | 131I-IPA |
|---|---|
| Also known as | 18F-FET |
| Sponsor | Telix Pharmaceuticals (Innovations) Pty Limited |
| Drug class | Somatostatin receptor targeting agent |
| Target | Somatostatin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
131I-IPA is a radioligand that targets the somatostatin receptor, allowing for targeted delivery of radiation to cancer cells.
Approved indications
- Prostate cancer
- Neuroendocrine tumors
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (PHASE3)
- 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (PHASE1)
- 131I-IPA and Concurrent XRT in Recurrent GBM (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 131I-IPA CI brief — competitive landscape report
- 131I-IPA updates RSS · CI watch RSS
- Telix Pharmaceuticals (Innovations) Pty Limited portfolio CI